These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17622505)

  • 1. [Prostate cancer screening with a new marker based on circulating blood macrophages?].
    Herwig R; Djavan B; Kramer G; El-Taieb MA; Kühhas F; Leers M; Marberger M
    Urologe A; 2007 Sep; 46(9):1066-70. PubMed ID: 17622505
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Lynch MJ
    J Urol; 2005 Sep; 174(3):1155; author reply 1155-6. PubMed ID: 16094096
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 4. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Hoeltl W; Müller MM; Lunglmayr G
    J Urol; 2005 Jun; 173(6):2205; author reply 2205-6. PubMed ID: 15879895
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum prostate-specific antigen: the most useful tumor marker.
    Andriole GL
    J Clin Oncol; 1992 Aug; 10(8):1205-7. PubMed ID: 1378885
    [No Abstract]   [Full Text] [Related]  

  • 7. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 8. Surgical perspective on prostate cancer. Detection, staging, and treatment.
    Loughlin KR
    Magn Reson Imaging Clin N Am; 1996 Aug; 4(3):449-69. PubMed ID: 8873013
    [No Abstract]   [Full Text] [Related]  

  • 9. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 11. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen. Improving its ability to diagnose early prostate cancer.
    Oesterling JE
    JAMA; 1992 Apr 22-29; 267(16):2236-8. PubMed ID: 1372945
    [No Abstract]   [Full Text] [Related]  

  • 13. The current management of carcinoma of the prostate.
    Rodriguez R; Carter HB
    Adv Surg; 1999; 33():181-97. PubMed ID: 10572567
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy.
    Zhang GM; Qin XJ; Zhang HL; Xiao WJ; Zhu Y; Gu CY; Dai B; Shi GH; Ye DW
    Asian J Androl; 2015; 17(2):239-44. PubMed ID: 25475662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is PSA density still useful in diagnosing prostate cancer?
    Pepe P; Candiano G; Fraggetta F; Galia A; Grasso G; Allegro R; Aragona F
    Arch Ital Urol Androl; 2009 Dec; 81(4):199-202. PubMed ID: 20608140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
    Partin AW; Walsh PC
    J Urol; 1994 Jul; 152(1):172-3. PubMed ID: 7515450
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating prostate-specific antigen/CD14-double-positive cells: a biomarker indicating low risk for hematogeneous metastasis of prostate cancer.
    Brandt B; Griwatz C; Brinkmann O; Zänker KS
    J Natl Cancer Inst; 1997 Jan; 89(2):174. PubMed ID: 8998191
    [No Abstract]   [Full Text] [Related]  

  • 18. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer: detection, staging, and treatment of localized disease.
    Potter SR; Partin AW
    Semin Roentgenol; 1999 Oct; 34(4):269-83. PubMed ID: 10553603
    [No Abstract]   [Full Text] [Related]  

  • 20. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.